Sign In
Buy MRK
$115.17
+0.270 (+0.235%)
At Close: Jun 16, 2026
Seagen's (SGEN) Q1 Earnings & Revenues Surpass Estimates
04:43pm, Friday, 29'th Apr 2022 Zacks Investment Research
Seagen (SGEN) reports narrower-than-expected loss in the first quarter of 2022 while its revenues beat estimates.
What This Regulatory News Could Mean for Merck
03:30pm, Friday, 29'th Apr 2022 The Motley Fool
Merck's Keytruda-chemotherapy combo could soon be approved to treat cervical cancer in the European Union.
Pharma Stock Roundup: Q1 Earnings of LLY, MRK & NVS, FDA Updates for AZN & PFE
02:32pm, Friday, 29'th Apr 2022 Zacks Investment Research
Eli Lilly (LLY), Merck (MRK), Novartis (NVS) and others announce Q1 results. FDA updates for AstraZeneca (AZN) and Pfizer (PFE) grab headlines in the pharma space.
Company News for Apr 29, 2022
01:34pm, Friday, 29'th Apr 2022 Zacks Investment Research
Companies In The News Are: TWTR, PYPL, MRK, MCD.
What 7 Analyst Ratings Have To Say About Merck & Co
01:23pm, Friday, 29'th Apr 2022 Benzinga
Over the past 3 months, 7 analysts have published their opinion on Merck & Co (NYSE:MRK) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company
Why Merck Crushed the Market Today
09:42pm, Thursday, 28'th Apr 2022 The Motley Fool
The company delivered resounding beats on both the top and bottom lines in its first quarter and raised guidance.
Dow, S&P 500 record best day in 7 weeks as tech stocks rally
08:26pm, Thursday, 28'th Apr 2022 MarketWatch
U.S. stocks end sharply higher Thursday, with the Nasdaq Composite leading the way up, as investors plow into technology stocks after earnings from Facebook parent Meta Platforms.
Markets Surge Despite Drop In US GDP
08:10pm, Thursday, 28'th Apr 2022 Benzinga
U.S. indices traded higher Thursday despite a drop in U.S. GDP. Strength in stocks is possibly due to better-than-expected quarterly earnings from multiple companies as well as a rebound following a s
Merck & Co. (MRK) Q1 2022 Earnings Call Transcript
04:30pm, Thursday, 28'th Apr 2022 The Motley Fool
MRK earnings call for the period ending March 31, 2022.
Alkermes (ALKS) Q1 Earnings Beat Estimates, Revenues Rise Y/Y
04:30pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Alkermes (ALKS) rides high on both earnings and sales beating estimates in the first quarter of 2022.
Could This FDA Approval Be a Boost for Merck?
02:23pm, Thursday, 28'th Apr 2022 The Motley Fool
Merck's mega-blockbuster Keytruda was given the nod to treat patients with a type of endometrial cancer in the U.S.
Boomers are leaving the stock market. Here's what comes next, says this strategist.
02:11pm, Thursday, 28'th Apr 2022 MarketWatch
Our call of the day from TS Lombard chief economist Steven Blitz warns that the "golden era of Fed-controlled equity markets" is nearing an end.
How Gilead is positioning Veklury against COVID-19 antivirals like Paxlovid
01:02pm, Thursday, 28'th Apr 2022 MarketWatch
The company has an oral version of its COVID-19 drug Veklury in a clinical trial.
Can a decades-old antidepressant keep COVID-19 patients out of the hospital?
01:00pm, Thursday, 28'th Apr 2022 MarketWatch
It's one of several generic drugs that's being tested as a way to treat the virus.
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
12:52pm, Thursday, 28'th Apr 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Moderna Seeks FDA Emergency Use Nod For COVID-19 Shot In Kids 2-6
Moderna Inc (NASDAQ: MRNA) submitt
